Prime Medicine (PRME) EBITDA Margin (2024 - 2026)

Prime Medicine posted quarterly EBITDA Margin of 5748.25% for Q1 2026, down 217837.0% year-on-year from N/an in Q1 2025, and down 4.65% on a QoQ basis from 5492.84% in Q4 2025.

Prime Medicine (PRME) has 3 years of EBITDA Margin data on file, last reported at 5748.25% in Q1 2026.

  • For the quarter ending Q1 2026, EBITDA Margin fell 217837.0% year-over-year to 5748.25%; the trailing twelve-month figure through Mar 2026 stood at 4917.2% (up 33321.0% YoY), and the FY2025 full-year result was 4340.7%, up 222538.0% from the prior year.
  • EBITDA Margin for Q1 2026 stood at 5748.25%, down from 5492.84% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1937.52% in Q4 2024 and bottomed at 25084.21% in Q3 2024.
  • The 3-year median for EBITDA Margin is 5104.54% (2025), against an average of 7303.88%.
  • Peak annual rise in EBITDA Margin reached 2095858 bps in 2025, while the deepest fall reached 355532 bps in 2025.
  • A 3-year view of EBITDA Margin shows it stood at 1937.52% in 2024, then tumbled by 183 bps to 5492.84% in 2025, then dropped by 5 bps to 5748.25% in 2026.
  • The last three EBITDA Margin figures came in at 5748.25% (Q1 2026), 5492.84% (Q4 2025), and 4125.63% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 38.10%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 18.35%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 17.24%
10 Prime Medicine 601.24 Mn 601.24 Mn - -5,748.25%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -5,748.25%
Dec 31, 2025 -5,492.84%
Sep 30, 2025 -4,125.63%
Jun 30, 2025 -4,716.23%
Mar 31, 2025 -3,569.88%
Dec 31, 2024 -1,937.52%
Sep 30, 2024 -25,084.21%
Mar 31, 2024 -7,756.51%